January 27, 2021 (Shanghai, China) -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on first-in-class therapies in oncology and immunology
December 21, 2020 (Shanghai, China) -- GenFleet Therapeutics, a clinical-stage biotechnology company developing first-in-class therapies in oncology and immunology worldwide
November 2, 2020 (Shanghai, China) - GenFleet Therapeutics, a clinical-stage biotechnology company focusing first-in-class therapies in oncology and immunology
March 8, 2020 (Shanghai, China) -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on first-in-class therapies in oncology and immunology
August 1, 2019 (Shanghai, China) – GenFleet Therapeutics completed the site initiation visit of Phase I trial for its first product granted with IND approval earlier this year.
November 30, 2018 (Shanghai, China) -- GenFleet Therapeutics recently announced the close of its series A financing worth 120 million yuan
